References
- Badawi N, Watson L, Petterson B, Blair E, Slee J, Haan E, Stanley F. What constitutes cerebral palsy?. Develop Med Child Neurol 1998; 40: 520–527
- Stanley F, Blair E, Alberman E. Cerebral palsies: Epidemiology and causal pathways. Clinics in Developmental Medicine No. 151. MacKeith Press, London 2000
- Watson L, Blair E, Stanley F. Report of the Western Australian cerebral palsy register to birth year 1999. Telethon Institute for Child Health Research, Perth 2007
- Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Develop Med Child Neurol 1997; 39: 214–223
- Graham H K. Classifying cerebral palsy (On the other hand). J Pediatric Orthop 2005; 25: 127–128
- Sanger T D, Delgado M R, Gaebler-Spira D, Hallett M, Mink J W. Task Force on childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111(1)89–97
- Delgado M R, Albright A L. Movement disorders in children: Definitions, classifications, and grading systems. J Child Neurol 2003; 18: S1–8
- Albright AL. Movement disorders in children – classification and recognition in New Approaches to the management of cerebral palsy: Accessed November 2006 at: http://video.wch.org.au/ortho/MD2006/1MovDisordsinchildren.pdf.
- ICON Proceedings Neurotoxin Institute from http://www.neurotoxininstitute.org/gt.asp?t=183.
- Marsden C D. The pathophysiology of movement disorders. Neurol Clin 1984; 2(3)435–459
- Bohannon R W, Smith M B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–207
- Boyd R N, Graham H K. Objective clinical measures in the use of Botulinum toxin A in the management of cerebral palsy. Eur J Neurol 1999; 6(Suppl. 4)S23–36
- Morris S. Ashworth and Tardieu scales: Their clinical relevance for measuring spasticity in adult and paediatric neurological populations. Phys Ther Rev 2002; 7: 53–62
- Love S. Better description of spastic cerebral palsy for reliable classification. Develop Med Child Neurol 2007; 49(Suppl.)S24–27
- Russman B S, Tilton A H, Gormley M E, Jr. Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Spasticity: Etiology, evaluation, management, and the role of Botulinum toxin, N H Mayer, D M Simpson. WE MOVE, New York 2002; 134–143
- Winters T F, Jr, Gage J R, Hicks R. Gait patterns in spastic hemiplegia in children and young adults. J Bone Joint Surg (Am) 1987; 69: 437–441
- Burns Y. Neuro Sensory Motor Developmental Assessment. CopyRight Publishing Company, Brisbane 1992
- Gibson N, Blair E, Valentine J, Pearce A. The use of botulinum toxin A to augment therapy in children with hemiplegia: A randomised trial investigating functional benefit. Develop Med Child Neurol 2006; 48(suppl. 105)4
- Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Develop Med Child Neurol 2006; 48: 170–175
- Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatrics 2000; 137: 331–337
- Wallen M A, O'Flaherty S J, Waugh M A. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: A phase II trial. Arch Phys Med Rehabil 2004; 85: 192–200
- Hoare B J, Imms C J. Upper limb injections of botulinum toxin A in children with cerebral palsy: A critical review of the literature and clinical implications for occupational therapists. Am J Occupat Ther 2004; 44: 389–397
- Love S C, Valentine J P, Blair E M, Price C J, Cole J H, Chauvel P J. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: A randomized controlled trial. Eur J Neurol 2001, suppl. 5: 50–58
- Graham H K, Aoki K R, Autti-Ramo I, Boyd R N, Delgado M R, Gaebler-Spira D J, Gormley M E, Guyer B M, Heinen F, Holton A F, Matthews, Molenaers G, Motta F, Garcia Ruiz P J, Wissel J. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000; 11: 67–79
- Graham H K, Selber P. Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg (Br) 2003; 85: 157–166
- Boyd R N, Hays R N. Outcome measurement of effectiveness of botulinum toxin type A in children with cerebral palsy: An ICIDH-2 approach. J Neurol 2001; 8(suppl. 5)167–177
- Graham H K, Tilton A. The use of botulinum toxin in spastic infantile cerebral palsy. Clinical applications of Botulinum toxin, D D Truong, D Dressler, M Hallett. Cambridge University Press, CambridgeUK 2008, (In press)
- Dodd K, Taylor N, Damiano D L. A systematic review of the effectiveness of strength-training programs for people with cerebral palsy. Arch Phys Med Rehabil 2002; 83(8)1157–1164
- Damiano D L, Quinlivan J M, Owen B F, Shaffrey M, Abel M F. Spasticity versus strength in cerebral palsy: Relationship among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 2001; 8(suppl. 5)40–49
- McPhail H EA, Kramer J F. Effect of isokinetic strength training on functional ability and walking efficiency in adolescents with cerebral palsy. Develop Med Child Neurol 1995; 37: 763–775